| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jerrold S Levine | |
| Michael J Fischer | |||
| Joyce Rauch | |||
| P2860 | cites work | Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines | Q22255576 |
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin | Q28185196 | ||
| A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome | Q28193536 | ||
| Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies | Q28203584 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis | Q33358476 | ||
| The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus | Q33360375 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment | Q33565796 | ||
| Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature | Q34977289 | ||
| The expanding spectrum of renal diseases associated with antiphospholipid syndrome | Q35140898 | ||
| Long term outcome of catastrophic antiphospholipid syndrome survivors | Q35552789 | ||
| Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome | Q35555909 | ||
| New treatments for antiphospholipid syndrome | Q36408003 | ||
| Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. | Q41109148 | ||
| Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. | Q43829967 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model | Q44652593 | ||
| beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome | Q45021710 | ||
| Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. | Q45034886 | ||
| IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis | Q45126748 | ||
| Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis | Q48394757 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| The intrarenal vascular lesions associated with primary antiphospholipid syndrome | Q74597824 | ||
| The antiphospholipid syndrome | Q77739053 | ||
| Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus | Q79171865 | ||
| New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials, and tribulations | Q79288146 | ||
| Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change | Q81441260 | ||
| P433 | issue | 1 | |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| P304 | page(s) | 35-46 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Seminars in Nephrology | Q15761561 |
| P1476 | title | The antiphospholipid syndrome | |
| P478 | volume | 27 |
| Q90312460 | Antiphospholipid Syndrome and Kidney Involvement: New Insights |
| Q35124252 | Association of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I. |
| Q37476170 | Catastrophic antiphospholipid syndrome presented with sudden renal failure and history of long-lasting psychosis and hypertension in a 42 years old women |
| Q54996884 | Cellular and Molecular Mechanisms of Anti-Phospholipid Syndrome. |
| Q58783569 | Extensive abdominal wall ulceration as a late manifestation of antiphospholipid syndrome: a case report |
| Q38646515 | Future research directions to improve fistula maturation and reduce access failure. |
| Q41788311 | Hypertension and renal failure with right arm pulse weakness in a 65 years old man |
| Q43672062 | IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality |
| Q37704874 | Isolated IgA anti- β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome |
| Q41203115 | Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis |
| Q37476122 | Prevalence of anti- beta2GPI antibodies and their isotypes in patients with renal diseases and clinical suspicion of antiphospholipid syndrome |
| Q41922298 | Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss |
| Q33390911 | Renal thrombotic microangiopathies/thrombotic thrombocytopenic purpura in a patient with primary Sjögren's syndrome complicated with IgM monoclonal gammopathy of undetermined significance |
| Q51278559 | Study of β2-Glycoprotein I Polymorphisms in Patients With Chronic Renal Failure as a Predisposing Factor for the Development of Anti-β2-Glycoprotein I Auto-Antibodies. |
| Q36716833 | The Biology of Hemodialysis Vascular Access Failure |
| Q35818105 | The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation |
| Q26775058 | The molecular mechanisms of hemodialysis vascular access failure |
| Q26825218 | What nephrolopathologists need to know about antiphospholipid syndrome-associated nephropathy: Is it time for formulating a classification for renal morphologic lesions? |
Search more.